Overall, while useful for PTC diagnostics, the use of NAT as the baseline for comparative gene expression studies may mask early changes preceding the appearance of histologically recognizable tumor that might enable deeper understanding of the requirements for PTC development, more might be influenced by changes in adjacent tissues that occur in response to the tumor. The gene discussed is BRD2; the disease is neoplasm.